HLA-G expression in human melanoma cells: Protection from NK cytolysis

Journal of Reproductive Immunology

Volumn 43, Issue 2, 1999, Pages 183-193

  Adrián Cabestré, Francisco ^a   Moreau, Philippe ^a   Riteau, Béatrice ^a   Ibrahim, El Chérif ^a   Le Danff, Caroline ^a   Dausset, Jean ^b   Rouas Freiss, Nathalie ^a   Carosella, Edgardo D ^a   Paul, Pascale ^a  

^a DIF   (France)

^b FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

HLA G; Melanoma cells; NK lysis; Tumor escape

Indexed keywords

HLA G ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CELL LINE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MELANOMA; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032776846     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0378(99)00037-6     Document Type: Article

References (19)

1. Borrego F., Ulbrecht M., Weiss E.H., Coligan J.E., Brooks A.G. Recognition of human histocompatibility leucocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187:1998;813-818.
2. Braud V.M., Allan D.S.J., O'Callaghan C.A., Söderström K., D'Andrea A., Ogg G.S., Lazetic S., Young N.T., Bell J.I., Phillips J.H., Lanier L.L., McMichael A.J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:1998;795-799.
3. Cantoni C., Verdiani S., Falco M., Pessino A., Cilli M., Conte R., Pende D., Ponte M., Mikaelsson M.S., Moretta L., Biassoni R. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the Ig superfamily. Eur. J. Immunol. 28:1998;1980-1990.
4. Carayol G., Robin C., Bourhis J.-H., Bennaceur-Griscelli A., Chouaib S., Colombel L., Caignard A. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur. J. Immunol. 28:1998;1991-2002.
5. Carosella E.D., Dausset J., Kirszenbaum M. HLA-G revisited. Immunol. Today. 17:1996;407-409.
6. Colonna M., Navarro F., Bellon T., Llano M., Garcia P., Samaridis J., Angman L., Cella M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186:1997;1809-1818.
7. Colonna M., Samaridis J., Cella M., Angman L., Allen R.L., O'Callaghan C.A., Dunbar R., Ogg G.S., Cerundolo V., Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 160:1998;3096-3100.
8. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.C., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor escape. Science. 274:1996;1363.
9. Kovats S., Main E.K., Librach C., Stubblebine M., Fisher S.J., DeMars R. A class antigen I, HLA-G, expressed in human trophoblasts. Science. 248:1990;220-223.
10. Lee N., Llano M., Carretero M., Ishitani A., Navarro F., Lopez-Botet M., Geraghty D.E. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA. 95:1998;5199-5204.
11. Meyaard L., Adema G.J., Chang C., Woolatt E., Sutherland G.R., Lanier L.L., Phillips J.H. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 7:1997;283-290.
12. Mingari M.C., Moretta A., Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today. 19:1998;153-156.
13. Mingari M.C., Ponte M., Bertone S., Schiavetti F., Vitale C., Bellomo R., Moretta A., Moretta L. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in suprantigen- or alloantigen-activated CD8+T cells. Proc. Natl. Acad. Sci. USA. 95:1998;1172-1177.
14. Moretta A., Biassoni R., Bottino C., Pende D., Vitale M., Poggi A., Mingari M.C., Moretta L. Major Histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155:1997;105-117.
15. Pardoll D.M. Cancer vaccines. Nature Med. 4:1998;525-531.
16. Paul P., Rouass-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G., Carosella E.D. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA. 95:1998;4510-4515.
17. Pazmany L., Mandelboim O., Vales-Gomez M., Davis D.M., Reyburn H.T., Strominger J.L. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science. 274:1996;792-795.
18. Rouas-Freiss N., Marchal-Bras Goncalves R., Menier C., Dausset J., Carosella E.D. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci. USA. 94:1997;11520-11525.
19. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc. Natl. Acad. Sci. USA. 94:1997;5249-5254.